• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

    US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

  2. TransMed7, LLC Announces 510(k) Submission to the U.S. FDA for Its SpeedBird Soft Tissue Biopsy Device Platform

    TransMed7, LLC Announces 510(k) Submission to the U.S. FDA for Its SpeedBird Soft Tissue Biopsy Device Platform

  3. Gilead Cell-Therapy Drug Yescarta Gets FDA Approval -- Update

    Gilead Cell-Therapy Drug Yescarta Gets FDA Approval -- Update

  4. AstraZeneca: FDA Accepts Imfinzi Supplemental Biologics License Application; Grants Priority Review

    AstraZeneca: FDA Accepts Imfinzi Supplemental Biologics License Application; Grants Priority Review

  5. UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

    UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

  6. UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

    UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

  7. UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

    UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

  8. UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

    UPDATE: Johnson & Johnson discards two hoped-for billion-dollar drugs

  9. Implanet Announces CE Mark Clearance for JAZZ® Passer

    Implanet Announces CE Mark Clearance for JAZZ® Passer

  10. President Trump reiterates that drug companies 'getting away with murder' but says not much else

    President Trump reiterates that drug companies 'getting away with murder' but says not much else

12345

©2017 Morningstar Advisor. All right reserved.